Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Pharmacopeia will reduce its workforce by approximately 15% to 150 in what the company calls an effort to focus resources on its clinical and late-stage drug discovery programs. Combined with other streamlining moves, the job cuts are expected to reduce operating expenditures by at least $10 million in 2009. Favrille, a biopharmaceutical firm focused on cancer and immune system therapies, will lay off 132 of its 144 employees following the disclosure that its non-Hodgkin's lymphoma therapy, Specifid, failed in Phase III trials. And Sunesis is reducing its workforce by about 60 people, or 60%, as it shifts its focus to developing its lead oncology product candidate, voreloxin.
This article has been sent to the following recipient: